The pharmaceutical firm expects marketing exclusivity.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) has obtained US Food and Drug Administration (FDA) approval for over-the-counter Famotidine tablets, a generic version of Johnson & Johnson - Merck Consumer Pharmaceutical's Pepcid Complete, an antacid for the treatment of heartburn
As the first company to file an Abbreviated New Drug Application (ANDA) for Famotidine, Perrigo said that it expects marketing exclusivity, and that it will begin shipments in the third quarter of 2008. Annual retail sales for Pepcid Complete chewable tablets are estimated at $95 million.
Perrigo rose 1.3% on Nasdaq yesterday but fell 2.3% by mid-afternoon on the TASE today.
Published by Globes [online], Israel business news - www.globes-online.com - on February 13, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008